6505--Nicotine Lozenges MINI (VA-26-00020754)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) has awarded a Firm Fixed-Price, Indefinite-Delivery Requirements contract (Award Number: 36E79726D0025) for Nicotine Polacrilex Mini Lozenges to PERRIGO DIRECT INC. This award, valued at $12,767,053.95, ensures a consistent supply of these products for the VA and Department of Defense (DoD) Pharmaceutical Prime Vendor Programs.
Scope of Work
The contract covers the procurement of Nicotine Polacrilex 2mg Mini Lozenges and 4mg Mini Lozenges, supplied in 81-count unit-of-use bottles. Key requirements included specific packaging dimensions, safety caps, unique barcodes, and an 11-digit NDC or UPC number for each product. Packaging could be individually boxed (with barcode on box) or meet unit of use requirements if not boxed. Offerors were required to ensure manufacturing facilities had acceptable cGMP status with the FDA and adhere to Drug Supply Chain Security Act (DSCSA) requirements. A 0.5% Cost Recovery Fee was also part of the pricing structure.
Contract & Timeline
- Contract Type: Firm Fixed-Price, Indefinite-Delivery Requirements
- Duration: One base ordering period (July 19, 2026, to July 18, 2027) with four pre-priced one-year option periods.
- Award Amount: $12,767,053.95
- Awardee: PERRIGO DIRECT INC
- Award Date: March 24, 2026
- Solicitation Number: 36E79726R0007
Set-Aside
This was an unrestricted acquisition. Subcontracting plan requirements applied to other than small businesses over $900,000.
Evaluation
Award was made to the responsible offeror with the lowest price technically acceptable offer. Technical acceptability included meeting product descriptions, NDC/UPC uniqueness, and FDA cGMP compliance for manufacturing facilities.
Additional Notes
The contracting office is the VA National Acquisition Center (NAC PHARMACEUTICALS). The Point of Contact for the original solicitation was Billy Fong (billy.fong@va.gov).